Happify Health and Almirall will start with a digital solution to help psoriasis patients

NEW YORK – (BUSINESS THREAD) – Today, Congratulations HealthIntelligent Healing Company ™, and Almirall SA (BME: ALM), A global biopharmaceutical company focused on skin health reported that Claro, a digital program developed through an innovative partnership between the two companies, is live and now available to people with psoriasis in Spain, Italy and the United Kingdom. Claro was built to improve the mental well-being of people with psoriasis through cognitive behavioral therapy, positive psychology, and mindfulness.

Psoriasis is one of the leading skin diseases affecting around 60 million people worldwide.2. A 2019 study in the journal Maedica, Clinical Medicine, establishes a clear link between the psychology of the skin of people with psoriasis and the quality of life.4. Between 20% and 30% of people with moderate to severe psoriasis also suffer from mental health problems, such as anxiety and depression.1. Eighty percent of people with psoriasis have mild to moderate symptoms, with direct health care costs for treating psoriasis exceeding $ 65 billion annually.3.

“At Almirall, we are proud to offer psoriasis patients a wide range of medications that cover the full spectrum of the disease, from mild to severe. Claro helps us meet our commitment to people with psoriasis by providing an improved solution to their well-being so that they can regain their lives, ”he said. Dr. Volker KoscielnyMD, Admiral’s Chief Medical Officer.

“This is a significant burden on the daily lives of 71% of people with psoriasis, according to the UK National Psoriasis Foundation.3“We are very pleased with the level of engagement we are seeing so far with Claro users,” said Theo Ahadome, Vice President of Marketing for Happify Health. to improve the quality of life “.

About the Admiral

Almirall is a global biopharmaceutical company focused on skin health. We work with scientists and health professionals to address the needs of patients through science to improve their lives. Our Noble Goal is at the core of our work: “Transforming the world of the sick by helping them realize their hopes and dreams for a healthy life.” We invest in a variety of medical dermatology products and pioneers to provide our patients with innovative solutions.

The company, founded in 1943 and headquartered in Barcelona, ​​is listed on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 78-year history, Admiral has maintained a strong focus on patient needs. Today, the Admiral has a direct presence in 21 countries and strategic agreements in more than 70, through 13 subsidiaries, with around 1,800 employees. Revenues for 2021 totaled € 836.5 million.

For more information, visit www.almirall.com

About Happify Health

Happify Health The Intelligent Healing Company ™ da. We bridge the gap between need and care by configuring personalized digital therapies and scale of care solutions for the modern cloud of healthcare. Our platform integrates IA with empathy, making healing more personal, accurate and connected throughout the care journey. We extend the full spectrum of clinical care solutions (including Digital Therapy, Coaching, Community and Wellness products) to the pharmacy, healthcare plans, businesses and individuals everywhere.

Our global platform is available in 10 languages, supports more than 10 chronic conditions, and spans more than 20 million lives.

References

  1. HL Richards, DG Fortune, CE Griffiths, CJ Main. Contribution of stigma perceptions to the disability of patients with psoriasis. J Psychosom Res., 50 (2001), pp. 11-15.

  2. National Psoriasis Foundation 2008 Survey Photo. Available at: PTT-24087-quality-of-life-issues-and-measurement-in-patients-with-psor (researchgate.net)

  3. EA Dowlatshahi, M. Wakkee, LR Arends, T. Nijsten. Prevalence and likelihood of symptoms of depression and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol., 134 (2014), 1542-1551 or.

  4. M. Esposito, R. Saraceno, A. Giunta, M. Maccarone, S. Chimenti. Italian study on psoriasis and depression. Dermatology., 212 (2006), pp. 123-127.

Leave a Comment